Premium
Muir‐Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores
Author(s) -
Vidal Claudia I.,
Sutton Angela,
Armbrect Eric A.,
Lee Jason B.,
Litzner Brandon R.,
Hurley M. Yadira,
Alam Murad,
Duncan Lyn M.,
Elston Dirk M.,
Emanuel Patrick O.,
Ferringer Tammie,
Fung Maxwell A.,
Hosler Gregory A.,
Lazar Alexander J.,
Lowe Lori,
Plaza Jose A.,
Robinson June K.,
Schaffer Andras
Publication year - 2019
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13459
Subject(s) - medicine , malignancy , immunohistochemistry , head and neck , oncology , pathology , dermatology , surgery
Background Muir‐Torre syndrome (MTS) is a rare inherited syndrome, with an increased risk of sebaceous and visceral malignancy. Prior reports suggest screening for mismatch repair (MMR) deficiency may be warranted in patients <50 years and when sebaceous neoplasms are located on a non‐head and neck location. Previously, appropriate use criteria (AUC) were developed for clinical scenarios in patients >60 years concerning the use of MMR protein immunohistochemistry (MMRP‐IHC). This analysis explores the appropriateness of testing in patients ≤60 years. Methods Panel raters from the AUC Task Force rated the use of MMRP‐IHC testing for MTS for previously rated scenarios with the only difference being age. Results Results verify the previously developed AUC for the use of MMRP‐IHC in neoplasms associated with MTS in patients >60 years. Results also show that in patients ≤60 years with a single sebaceous tumor on a non‐head and neck site, MMRP‐IHC testing should be considered. Testing can also be considered with a 2‐antibody panel on periocular sebaceous carcinoma in younger patients. Conclusions Our findings align with known evidence supporting the need to incorporate clinical parameters in identifying patients at risk for MTS, with age being a factor when considering MMRP‐IHC testing.